Overview

• Cellebrite Q2 revenue grows 18% yr/yr, beating analyst expectations, per LSEG data

• Adjusted EBITDA for Q2 beats estimates, reflecting a 29% increase, per LSEG data

• Net income for Q2 misses analyst expectations, per LSEG data

Outlook

• Cellebrite expects Q3 revenue between $121 mln and $126 mln

• Full-year 2025 revenue forecasted at $465 mln to $475 mln

• Company anticipates Q3 adjusted EBITDA of $31 mln to $34 mln

• Full-year adjusted EBITDA expected to be $118 mln to $123 mln

• Pending acquisition of Corellium expected to enhance digital investigation capabilities

Result Drivers

• SUBSCRIPTION REVENUE - Subscription revenue increased 21% yr/yr, contributing to overall revenue growth

• GROSS PROFIT - GAAP gross profit and gross margin of $95.6 million and 84.4%, respectively; Non-GAAP gross profit and gross profit margin of $96.4 million and 85.1%, respectively

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the software peer group is "buy"

• Wall Street's median 12-month price target for Cellebrite DI Ltd is $24.50, about 42.9% above its August 13 closing price of $13.99

• The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release: ID:nGNX2GF7Gt

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)